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ABSTRACT 
HYPERHOMOCYSTEINEMIA ALTERS SINOATRIAL AND ATRIOVENTRICULAR 
NODAL FUNCTION: ROLE OF THE CARDIAC NMDA RECEPTOR 
Chirag V. Soni 
August 27,2012 
Introduction: Hyperhomocysteinemia (HHcy) is a pathological condition characterized 
by excessive levels of plasma homocysteine (Hcy). Patients with HHcy are reported to be 
at risk for arrhythmias like atrial fibrillation and sudden cardiac death (SCD); however, 
the causative mechanisms remain unknown. The effects of HHcy on sinus node function, 
atrioventricular conduction and ventricular vulnerability were investigated by in vivo 
electrophysiological (EP) analysis, and the role of the cardiac N-methyl-D-aspartate 
receptor (NMDA-R) in promoting Hcy-induced conduction abnormalities was explored. 
Materials and Methods: Anesthetized wild-type control mice (WT), mice receiving Hcy 
in the drinking water for 12 weeks (DW), and heterozygous cystathionine-~-synthase 
knockout mice (CBS+1-) were subjected to electrocardiographic (ECG) analysis and 
programmed electrophysiological (EP) studies. To examine the role of the NMDA-R in 
eliciting conduction changes in HHcy, animals from the three groups were subjected to 
paired-design repeat EP studies before and after intraperitoneal injection of magnesium 
sulfate (MgS04, 20mg/kg), an endogenous blocker of NMDA-R. Another set of studies 
v 
utilized a specific NMDA-receptor antagonist, dizocilpine (MK-801), in similarly paired-
design studies in an acute, intraperitoneal infusion model of HHcy. Expression levels of 
cardic NMDA-R in all three groups of animals were quantified by immunoblotting, and 
immunohistochemical identification of cardiac NMDA-Rs at the mouse atrioventricular 
(A V) junction was undertaken. 
Results: DW compared to WT had significantly shorter RR, PR, QT, and HV intervals, 
corrected sinus node recovery times (CSNRT), Wenckebach periodicity (WP), AV nodal 
effective refractory periods (A VNERP), and right ventricular effective refractory periods 
(RVERP). No ventricular arrhythmias were induced in either WT or DW. In the paired-
design studies, blockade of cardiac NMDA-R with MgS04 had no effect on any ECG or 
EP variables in WTbut significantly prolonged RR, QT, HV, CSNRT, WP, and 
AVNERP in DWand CBS+1- animals. Immunopositive staining for cardiac NMDA-R at 
the mouse A V junction was detected. 
Conclusions: Significant changes in conduction were observed between wild-type mice 
and mice with diet-induced or genetically-induced hyperhomocysteinemia (HHcy). Low-
dose magnesium administration did not alter ECG or EP conduction variables in wild-
type mice, but had a profound effect on mice with HHcy. These results suggest that 
shortened sinoatrial and atrioventricular conduction time in mild HHcy may involve 
cardiac NMDA-Rs. 
vi 
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CHAPTER I 
INTRODUCTION 
Increased plasma homocysteine (Hcy) is an independent risk factor for a 
significant number of cardiovascular diseases, including hypertension, coronary artery 
disease, atherosclerosis, and heart failure. Recent reports demonstrate a link between 
hyperhomocysteinemia (HHcy) and arrhythmogenesis leading to atrial fibrillation (AF) 
as well as lethal arrhythmias leading to sudden cardiac death (SCD). The exact 
mechanism by which higher levels of Hcy may facilitate induction of arrhythmias has not 
been elucidated. 
Hcy is known to activate the N-methyl-D-aspartate receptor (NMDA-R) in the 
brain, increasing intracellular calcium [Ca2+]i and the excitability of cells). The NMDA-
R is expressed in several peripheral tissues, including the heart, kidney, lungs, testes, GI 
trace as well as in the vascular endothelium3 and smooth muscle4. In the heart it has been 
identified in both the myocardium as well as in the specialized conductive tissuess, 6. 
Although subunits of NMDA-R are expressed in various cardiac cells, the role of cardiac 
NMDA-Rs in normal or pathological cardiac conduction is unknown. 
Additionally, HHcy induces mitochondrial oxidative stress of cardiomyocytes, 
increasing levels of reactive oxygen species (ROS) which activate matrix 
metalloproteinases (MMPs) involved in extracellular matrix (ECM) remodelling7, 8. 
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MMP-mediated remodelling is a ubiquitous phenomenon that results in the degradation 
and recycling of membrane-associated proteins, including ion channels like the N-
methyl-D-aspartate receptor (NMDA-R), and connexins (Cxs) which mediate 
intercellular communication via formation of gap junction channels (GJCs). Changes in 
NMDA-R subunit composition and receptor density can alter cell-to-cell signal 
propagation in the myocardium and the specialized conduction system (SCS) of the heart. 
Communication between cells at the sinoatrial node (SAN), internodal pathways, 
atrioventricular node (A VN) and His-Purkinje fibers could be altered by MMP-mediated 
remodelling in patients with HHcy. Changes in NMDA receptor subunit expression can 
have a profound effect on normal impulse propagation, but more importantly on signal 
conduction between atria and ventricles across the A VN. 
The overall hypothesis of this dissertation was arrhythmogenesis may arise in 
HHcy due to higher circulating levels of Hcy, which acts as an agonist at the cardiac 
NMDA receptor. This hypothesis was tested by 1) measuring electrocardiographic (ECG) 
and electrophysiological (EP) variables in order to compare cardiac conduction in wild-
type and hyperhomocysteinemic mice, 2) characterizing the role of cardiac NMDA-R in 
the conduction changes observed in HHcy by utilizing pharmacological inhibition of the 
receptor, and 3) comparing cardiac NMDA receptor expression levels in wild-type and 
HHcy mice. In this dissertation, evidence that supports potential mechanisms by which 
increased plasma Hcy may increase nodal cell excitability, and thereby facilitate the 
initiation of arrhythmias, is presented. 
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BACKGROUND 
Homocysteine 
Homocysteine (Hcy) is a non-proteinogenic, sulfur-containing excitatory amino 
acid. It is similar to cysteine, another thiolated amino acid which is formed using Hcy as 
a precursor, except that Hcy contains one more methylene group (CH2). It is generated as 
a consequence of methionine metabolism, and is involved in the transmethylation and 
trans-sulfuration pathways. In the transmethylation pathway, methionine, which is orally 
consumed as protein, becomes adenosylated via transfer of adenosine from ATP by 
methionine adenosyltransferase. This forms S-adenosylmethionine (SAM) which is a 
universal methyl group (-CH3) donor. Methyl transferases, such as those which catalyze 
the methylation of DNA and RNA, transfer the methyl group bonded to the sulfur atom in 
SAM to its target. Phenylethanolamine-N-methyltransferase (PNMT) uses SAM to 
donate a methyl group to norepinephrine to produce epinephrine. Once SAM is de-
methylated, it becomes S-adenosylhomocysteine (SAH). SAH is hydrolyzed by SAH 
hydrolase to yield homocysteine. 
Hcy at this point can continue in the transmethylation pathway and be 
remethylated to methionine, or it can be further metabolized by the trans-sulfuration 
pathway. In the transmethylation pathway, methionine can be regenerated from 
homocysteine by methionine synthase (MS), which is another methyltransferase. 5-
methyltetrahydrofolate, which is formed following the vitamin Bl2-dependent reduction 
of 5, lO-methylenetetrahydrofolate by methylenetetrahydrofolate reductase (MTHFR), is 
used as a methyl donor by MS to re-methylate Hcy and regenerate methionine. In the 
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trans-sulfuration pathway, Hcy condenses with serine to form cystathionine via a vitamin 
B6-dependent reaction catalyzed by cystathionine-~-synthase (CBS). Cystathionine is 
cleaved to create cysteine and a-ketobutyrate by cystathionine-y-Iyase (CGL), which is 
also vitamin B6-dependent. Cysteine can be further metabolized by the trans-sulfuration 
pathway to form glutathione, an important cellular antioxidant. 
Accumulation of Hcy 
Elevated plasma and tissue accumulation of Hcy can arise in several ways. As 
previously described, Hcy is generated as methionine is converted to SAMISAH. 
Increased dietary intake of methionine can therefore lead to higher levels of Hcy. Also, 
increased activity of methyl transferases will yield more SAH, and therefore more Hcy, 
following methylation reactions. In addition, genetic polymorphisms have been identified 
in several of the enzymes involved in the transmethylation and trans-sulfuration 
pathways. Genetic polymorphisms in MTHFR, CBS, MS, and MS reductase have been 
identified, and several of these are associated with varying degrees of 
hyperhomocysteinemia or homocystinuria, an inherited disorder affecting the metabolism 
of sulfur-containing amino acids9. One of the most extensively studied MTHFR 
polymorphisms, the substitution of C---+T at nucleotide position 677 (C677T) which 
results in the substitution of valine for alanine, causes enzyme deficiency wherein 
homozygous individuals have MTHFR enzyme activity reduced to 30% of wild-type 
activitylO. Over 100 different mutations have been identified in the CBS gene, and many 
have been linked to varying degrees of hyperhomocysteinemia ll . The classical genetic 
disease homocystinuria, caused by a CBS deficiency, results in extremely high levels of 
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plasma and urinary homocysteine and methionine. Homocystinurics present with mental 
retardation, musculoskeletal deformities, motor and gait dysfunction, and ectopia lentis9. 
B vitamin deficiency can also cause elevated levels of Hcy, since several of the 
enzymes involved in Hcy metabolism require B vitamins as cofactors (MTHFR requires 
B12, CBS and COL both require B6). Folate (B9) is also required - the tetrahydrofolate 
cycle provides the methyl group required to regenerate methionine from Hcy. Without 
proper intake of B vitamins these processes will be hindered, resulting in increased 
plasma Hcy. Indeed, B vitamin supplementation is shown to decrease plasma Hcy. 
Renal dysfunction can also lead to HHcy. Plasma Hcy levels are determined by 
intracellular metabolism of Hcy, import/export of Hcy between the plasma and the 
various tissues most largely associated with Hcy metabolism12, and renal clearance of 
Hcy. Renal clearance of Hcy is hindered in patients with renal disease/dysfunction, 
resulting in the accumulation of Hcy in the plasma. 
Normal fasting plasma Hcy values generally fall within 5-10 !AM. Values greater 
than 10 !AM (10-30 !AM) are considered mildly hyperhomocysteinemic. Moderate HHcy 
is characterized by plasma Hcy values between 30-100 !AM, and severe HHcy is 
characterized by plasma Hcy levels above 100 !AM. 
Hey and Disease 
Kilmer S. McCully first postulated the homocysteine theory of arteriosclerosis in 
1975 13. It is now well-established that increased plasma Hcy is a risk factor for 
cardiovascular, cerebrovascular, and neurodegenerative disease. High plasma Hcy levels 
have been linked to coronary artery disease, hypertension, acute myocardial infarction, 
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stroke, atherosclerosis, heart failure, atrial fibrillation, and sudden cardiac death (SCD)9, 
14-23. Increased plasma Hcy is also a risk factor for neurologic disorders like Alzheimer's 
and Parkinson's diseases, as well as psychiatric disorders like schizophrenia. 
Cardiac Arrhythmias in HHcy 
The risk factors for arrhythmogenesis are multifactorial. HHcy is associated with 
hypertension, coronary artery disease, and cardiac interstitial fibrosis24. The presence of 
one or a combination of these risk factors induces structural derangements to the 
ventricular myocardium, thereby increasing the chance of creating substrate for the 
induction of ventricular tachycardia (VT) and possibly ventricular fibrillation (VFib). In 
the absence of intervention, VT degenerates into VFib and sudden cardiac death (SCD). 
Several studies associate elevated Hcy with SCD9, 14, 16. 
Additionally, several studies assert an association between HHcy and atrial 
fibrillation25 , especially in the context of the thrombogenic potential of increased plasma 
Hcy and the consequent risk of stroke22, 23. Atrial fibrillation arises due to extensive 
structural and electrical atrial remodelling. HHcy-induced MMP activation plays a role in 
the structural and electrical remodelling of the atria26, 27. Following orthotopic heart 
transplantation, HHcy is associated with altered atrial electrical conduction manifesting 
as P wave dispersion28. Hcy also modulates sodium and potassium currents in human 
atrial myocytes29, 30, highlighting another plausible mechanism by which elevated Hcy 
may initiate atrial arrhythmias. 
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Cardiac Action Potentials 
The basis for cardiac impulse generation and conduction is cardiac cell 
excitability and spatiotemporal ionic permeability changes. Ionic conductances through 
specific types of N a +, K+, and Ca2+ channels underlie the different phases of the cardiac 
action potential, as well as the different morphologies of action potentials elicited by the 
various cardiac tissues. 
The cardiomyocyte action potential typically has four phases: in Phase 4 the cell 
is at rest, rapid depolarization occurs during Phase 0, early repolarization begins during 
Phase 1, delayed repolarization and a slow inward calcium current underlie the plateau of 
Phase 2, and repolarization is completed during Phase 3. Not all cardiac action potentials 
exhibit all four phases. Nodal cells of the specialized conduction system only exhibit 
three phases: an unstable Phase 4, Phase ° depolarization, and Phase 3 repolarization. The 
unstable Phase 4 of nodal cells is responsible for cardiac automaticity. 
In working myocytes, an inward sodium current (INa) activated by opening of 
Nav1.5 (SCN5A) voltage-gated sodium channels causes the rapid phase ° depolarization. 
The phase 1 repolarization is mediated by a transient outward K+ current (Ito) mainly 
through KA.3 (KCND3) assembled voltage-gated K+ channels. The plateau in phase 2 is 
due to opening of L-type voltage-gated calcium channels (Cavl.2), giving rise to inward 
conductance ICa,L' Repolarization is mediated by three outward delayed-rectifier K+ 
channels: at the beginning of phase 2, the ultra-rapidly activating delayed-rectifier K+ 
channel (Kv1.5/3.1) permits outward current IKur; midway through phase 2 the slowly 
activating delayed-rectifier K+ channel (KvLQTl) opens to conduct IKs ; finally, late 
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repolarization in phase 3 is mediated by the rapidly activating delayed-rectifier K+ 
channel (hERG), which conducts IKr. 
An important difference between nodal cells and cells of the working 
myocardium is that nodal cells of the proximal conduction system lack the fast, voltage-
gated Na+ channel (Nay 1.5) responsible for rapid phase 0 depolarization in working 
myocytes. The Purkinje fibers of the distal conduction system, however, do express the 
fast Na+ channels; this allows the Purkinje network to rapidly convey action potentials to 
the ventricular endocardium and epicardium. Phase 0 depolarization in nodal cells is 
mediated by activation of T -type voltage-gated calcium channels (Cay3.l, ICa,T) as well as 
the L-type channels found in non-pacemaker cells. Additionally, nodal cells express 
channels which give rise to the "funny" current If, also known as the pacemaker current. 
Hyperpolarization-activated, cyclic nucleotide-gated (HCN) channels at the sinoatrial 
node are responsible for the unstable phase 4 which confers automaticity. HCN channels 
are expressed at the A V node as well as in Purkinje fibers. 
There are other currents which playa role in shaping the cardiac action potential, 
namely other K+ currents such as the ATP-gated IKATP, acetylcholine-gated IKAch, and 
voltage-gated inward-rectifying IKI currents. 
Glutamate Receptors--The NMDA Receptor 
Although they have been most extensively studied in the brain, glutamate 
receptors (GluRs) are present in many tissues outside the nervous system, including the 
heart6, 31. GluRs are activated by the excitatory amino acid L-glutamate and are divided 
into 2 SUbtypes: metabotropic glutamate receptors (mGluRs) and ionotropic glutamate 
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receptors (iGluRs). Both types, when activated, result in an increase in intracellular Ca2+ 
by different mechanisms. Metabotropic GluRs are G-protein-coupled receptors; binding 
of glutamate to mGluRs initiates signal transduction events such as activation of 
phospholipase C, which hydrolyzes phosphatidylinositol-4,5-bisphosphate (PIP2) into 
inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). Subsequently, IP3 activates 
the release of intracellular Ca2+ from stores within the sarcoplasmic reticulum. Acidic 
derivatives of Hcy, like homocysteic acid (HcyA), activate mGluRs in neuronal and non-
neuronal tissues32, initiating G-protein mediated signalling and causing an increase in 
[Ca2+]j. mGluRs have also been identified in mammalian heart33 . 
Ionotropic GluRs are present in various mammalian tissues as well3), 34. There are 
3 classes of iGluRs, each named after its highest affinity agonist: N-methyl-D-aspartate 
(NMDA) receptors, alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid 
(AMPA) receptors (also known as quisqualate receptors), and kainate (Ka) receptors. 
Activation of iGluRs predominantly induces Ca2+ influx, besides permitting Na+ influx 
and K+ efflux, causing depolarization and excitation of the cells. The NMDA receptor is 
unique in that its activation is both ligand- and voltage-dependent. Both glutamate and 
the co-agonist glycine are required to bind, and a voltage-dependent Mg2+ block 
occluding the central pore must be relieved by local membrane depolarization before the 
channel becomes permeable to Ca2+, Na2+, and K+. 
Most NMDA receptors are assembled from NR 1 subunits (of which there are 
eight alternative splice variants) and NR2 subunits (of which there are 4 isoforms, NR2A-
D). NR3 subunits have also been identified, which confer an inhibitory effect on the 
receptor. NRI and NR2 subunits contain binding sites for glycine and glutamate, 
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respectively. Hcy activates the NMDA-R in neurons I , endothelial cells3, and vascular 
smooth muscle cells4. Hcy is capable of binding to both the glycine and glutamate 
binding sites of NMDA-R. Interestingly, Hcy acts as an agonist at the glutamate binding 
site on NR2, but acts as a partial antagonist at the glycine binding site on NR II. Glycine 
elevated above physiological levels therefore increases the agonistic effects of Hcy. 
Supporting evidence that excitatory amino acids acting on the NMDA-R playa 
role in arrhythmogenesis is a study demonstrating that blockade of the receptor decreases 
ischemiaireperfusion-induced arrhythmias but not ischemia-induced arrhythmias35. These 
findings suggest that circulating factors are involved in arrhythmia induction; also in the 
setting of myocardial ischemiaireperfusion, blocking the NMDA-R is important in 
reducing arrhythmogenic substrate. In this context, exposure to high levels of Hcy or 
other circulating excitatory amino acids may overactivate the cardiac NMDA-R, 
increasing [Ca2+]j and altering the rate of cell-to-cell conduction, thereby creating 
arrhythmogenic substrate. 
Hey and Oxidative Stress 
Increased plasma Hcy induces oxidative stress by activating inducible nitric oxide 
synthase (iNOS) and NADPH oxidase 7, 36-38. Both contribute to the formation of reactive 
oxygen species (ROS) and reactive nitrogen species (RNS) like peroxide (H20 2), 
superoxide (02-), hydroxyl radical (OH), and peroxynitrite 7. Increased levels of 
myocardial iNOS are associated with arrhythmogenesis and SCD39. HHcy increases 
mitochondrial oxidative stress of cardiomyocytes, increasing levels of ROS which 
activate matrix metalloproteinases (MMPs) involved in extracellular matrix (ECM) 
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remodelling8. Hey also diminishes activity of superoxide dismutase (SOD) and many 
redoxins which reduce ROS, further exacerbating oxidative stress 7. 
It is established that Hey activates MMPs by oxidizing inhibitors of MMPs, such 
as tissue and cardiac inhibitors of MMPs (TIMPs and CIMPs, respectively). Latent 
MMPs associate with nitric oxide (NO) and TIMPs in a ternary complex; ROS and RNS 
generate nitrosylated tyrosine residues in TIMPs, thereby liberating active MMPs 7,40. 
Overactivation of MMPs is responsible for abnormal myocardial remodelling, which 
results in increased interstitial collagen associated with fibrosis 24. In paradigms where 
cardiac remodelling associated with fibrosis occurs (e.g. heart failure, myocardial 
infarction or atrial fibrillation), an increased likelihood of re-entrant arrhythmias is a 
common feature. Conduction abnormalities observed in infarction and cardiac failure 
appear to be related to connexin dysfunction and increased action potential duration 
(APD), whereas in atrial fibrillation, reduction of APD appears to playa major role41 . 
Connexins 
Intercellular communication between cardiomyocytes, nodal cells, and endothelial 
cells is important in the coordinated excitation and contraction of the working 
myocardium, as well as in impulse propagation through the SCS of the heart. Intercellular 
communication is mediated by gap junction channels (GJCs) composed of connexins 
(Cxs). Six connexins join to form a connexon (a hemichannel assembly comprising half 
of a GJC) which communicates with a hemichannel from an adjacent cell to form a 
functional GJC between the two cells. The selective permeability, unitary conductance of 
ions, and gating characteristics of an assembled GJC is determined by the Cx isotype 
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composition of the channels. Twenty-one human Cx isoforms have been identified, with 
five present in the heart: Cx31.9, Cx37, Cx40, Cx43, and Cx45 41-48. The latter three have 
been extensively studied in the heart. Cx43 is the most abundantly expressed Cx in the 
heart; it is present in the atrial and ventricular working myocardium, as well as the distal 
SCS 41,42. GJCs composed entirely of Cx43 allow a unitary conductance of 115-120 
picoSiemens (pS) 49,50. Cx40 is present in and around the AVN, as well as in the atrial 
myocardium 41. Channels composed ofCx40 allow faster conductance at 180-200 pS 50, 
51. Cx45 is found in the SAN, AVN, and the internodal conduction system 52. Cx45 
channels exhibit slower unitary conductance, at 35 pS 53. A recently discovered connexin 
isoform Cx31.9 in humans (Cx30.2 in mouse) is thought to playa role in slowing the 
impulse conduction across the A VN 54, 55. Cx31.9 is predominantly localized to the SAN 
and A VN, and allows the slowest conductance, at 9 pS 50,54,55. 
Assembly of Cxs into hemichannels, and ultimately into GJCs, can result in 1 of 3 
types of channels. Homotypic channels are composed of the same Cx isotypes in both 
hemichannels. Heterotypic channels are formed by hemichannels assembled from 1 
isotype apposed to hemichannels composed entirely of a different Cx isotype. 
Heteromeric channels are the most variable; each hemichannel can have a variable Cx 
isotype configuration. If you consider only 2 of the 21 identified Cx isoforms, which can 
be assembled into any configuration of hemichannels and GJCs, there would be at least 
196 different channel configurations 56. Due to the several possible configurations of 
heterotypic and heteromeric channels, the permeability, conductance, and gating 
properties of each channel varies as the summation of the properties of individual Cx 
subunits. In HHcy, activation of MMPs induces MMP-mediated cardiac remodelling 24, 
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and as observed in heart failure and myocardial infarction 57-62, remodelling alters the 
expression, distribution, and regulation of Cxs, ultimately modifying electrical continuity 
between cardiac cells. 
Cardiac Remodelling and Cx Dysfunction 
Cardiac remodelling in patients with heart failure is associated with various types 
of arrhythmias and conduction abnormalities 63. A common finding in these patients is 
down-regulation and dysfunction of Cx43 57-59. Changes in Cx43 expression may be 
regionally determined and aggravated by dyssynchronous contraction 57,64. Similarly, 
conduction abnormalities are frequently found in patients with healed myocardial 
infarctions. Surviving cells in the peri-infarct zone have abnormal action potentials due to 
abnormal cell coupling 53,65. Significant changes in GJC organization and distribution of 
Cx43 occur in healed myocardial infarctions 60-62. In experimental studies, genetically 
engineered mice expressing <50% of normal Cx43 levels exhibit increased propensity 
towards arrhythmic activity in response to acute ischemia 66. Targeted inactivation of 
Cx43 in myocardium leads to increased arrhythmic activity and sudden death 67, 68. In 
heart failure and myocardial infarction, activation of c-Jun N-terminal kinase (JNK) 
appears to be the mechanism by which Cx43 is down-regulated 69. In addition to 
decreasing Cx43 expression, phosphorylation changes impairing Cx43 function 
effectively reduce cell-to-cell communication 58,59. 
Conduction is further impaired in heart failure and myocardial infarction by 
lateralization of GJCs and increased heterogeneity of Cx isotypes in hemichannels 60,70. 
In normal hearts, GJCs are primarily localized at the end-to-end junctions of adjacent 
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myocytes. In healed myocardial infarction there are fewer and smaller GJCs, with a 
change in proportion of side-to-side versus end-to-end intercellular connections 60. In 
heart failure, the percentage of lateralized GJCs expressing Cx43 increases along the 
length of myocytes while end-to-end connections decrease 70. Furthermore, increased 
Cx43 heterogeneity in heart failure patients is associated with VT 71. Recent studies 
demonstrate that homotypic Cx43 and Cx45 GJCs have higher conductance than 
heterotypic and heteromeric (Cx43 and Cx45 combined) GJCs 72,73. Since Cx43 is down-
regulated in heart failure and Cx45 levels are unchanged or increased, the Cx45:Cx43 
ratio increases, potentially promoting the formation of more heterogeneous GJCs with 
lower conductance than in normal hearts 56, 73. 
The similarity of events in HHcy-, heart failure- and myocardial infarction-
induced remodelling supports the hypothesis that elevated levels of Hcy may create 
arrhythmogenic substrate. In fact, recent evidence demonstrates that long-term diet-
induced HHcy down-regulates Cx43 expression74. Down-regulation of Cx43 expression 
in heart failure produces a positive feedback system in which slow ventricular impulse 
conduction contributes to mechanical dysfunction, and further promotes ventricular 
remodelling 64. Impaired impulse conduction also creates substrate for re-entrant 
arrhythmias 57. These arrhythmias require two parallel conducting pathways connected 
proximally and distally by conducting tissue, thus forming a potential electric circuit. For 
re-entry to occur 3 prerequisites need to be present: 1) one of the two pathways conducts 
more slowly, 2) the faster conducting pathway has a substantially longer refractory 
period, and 3) an appropriately timed premature impulse is needed to initiate a continuous 
circular propagation of the impulse. In heart failure, subepicardial Cx43 expression is 
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reduced by approximately a third compared with deeper layers of the left ventricle, 
accentuating uncoupling between the epicardial-midmyocardial interface 57. The 
development of steep gradients of repolarization occurring within the epicardial-
midmyocardial interface underlies the mechanism of conduction block and re-entrant 
arrhythmogenesis in heart failure 70. However, in HHcy-induced ventricular remodelling, 
the levels of Cx43 expression and function at the various myocardial layers have not been 
studied, therefore it is unknown whether uncoupling of myocardial layers due to HHcy is 
of sufficient magnitude to create re-entrant substrate. 
Remodelling at the SAN and A VN 
The sinoatrial node (SAN) and atrioventricular node (AVN) are part of the heart's 
SCS. The SAN is specialized in pacemaking, whereas the A VN is responsible for 
propagating cardiac impulses from the SAN to the ventricles. The A VN has two 
important functions: 1) reduce impulse conduction velocity to allow time between atrial 
and ventricular depolarization, thereby allowing time for ventricular filling prior to 
systole, and 2) protect ventricles from premature aberrant beats generated in the atria. To 
perform their functions, both the SAN and A VN have special requirements regarding the 
electrical coupling between cells, which is determined by Cx isoform expression in GJCs. 
The electrical coupling of cells at the center of the SAN needs to be weak to protect them 
from the inhibitory electrotonic influence of hyperpolarized non-pacemaking atrial 
myocytes surrounding the SAN. Conversely, for the SAN to be able to drive the atrial 
muscle, electrical coupling should be strong in the periphery of the SAN 75. Indeed, at the 
center of the mouse SAN there is little or no expression of high conductance Cx40 and 
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Cx43 (the principal Cxs of cardiac muscle), but there is expression of lower conductance 
Cx45 and Cx30.2, whereas in the periphery of the SAN, Cx43 as well as Cx45 is 
expressed 55. In the A VN, a similar pattern of Cx expression as in the center of the SAN 
is observed; cell-to-cell coupling is mediated by abundant expression of Cx30.2 and 
Cx45, and to a lesser extent expression of Cx40 55. This Cx expression pattern is likely to 
be in large part responsible for the slow conduction of the action potential. In heart 
failure patients, atrial remodelling is characterized by abnormalities of conduction, sinus 
node dysfunction, and structural changes along the crista terminalis. These abnormalities 
may be responsible in part for the increased propensity for atrial fibrillation in heart 
failure 76, 77. 
At present, it's unknown whether HHcy-induced cardiac remodelling has an 
effect on SAN function. However, recent evidence from electrophysiological studies 
indicates that in diet-induced HHcy, atrioventricular (AV) conduction is altered78 • 
Anatomically, the AVN is not as discrete a body as the SAN, and the modern view 
describes it as a dual atrioventricular transmission system wherein diffuse fibers arising 
in the right atrium coalesce into two pathways which approach the central, compact body 
of the A VN 79, so. The anterior pathway, which runs along the Tendon of Todaro, has 
been determined to be the fast (or normal) pathway with a longer refractory period. The 
posterior pathway, running along the tricuspid annulus, comprises the slow pathway with 
a shorter refractory period. The existence of dual pathways with differing conduction 
velocities has been hypothesized to be the substrate for A V nodal re-entrant 
supraventricular arrhythmias 79, SI. The question however is whether MMP-mediated GJC 
remodelling, induced by pathological conditions such as HHcy, alters A V nodal Cx 
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expression (Cx30.2, Cx45, and Cx40) to sufficiently create re-entrant substrate. Recent 
studies have provided biochemical evidence for the ability of Cx30.2 to hetero-
oligomerize with the other cardiac Cxs 82. In cells expressing Cx43 and Cx45, the 
introduction of Cx30.2 alters the properties of GJC currents to an intermediate level 
between that of either Cx alone. These intermediate properties may be explained by the 
formation of heteromeric GJCs or they might correspond to the aggregate of a mixture of 
homomeric GJCs. In contrast, when Cx40 and Cx30.2 are co-expressed, the physiological 
properties of GJCs are similar to those in cells expressing Cx30.2 alone; these findings 
can be explained by the formation of heteromeric GJCs. In these studies, Cx45 
expression showed the most extensive overlap with regions of Cx30.2 expression; thus 
Cx30.2-Cx45 interactions may influence conduction in those areas 82. Studies using 
genetically altered animals have shown that Cx40 deficient mice exhibit slower A V nodal 
conduction 83. Conversely, mice deficient in Cx30.2 exhibit faster AV conduction54. The 
latter study demonstrates the important role Cx30.2 plays in the slowdown of impulse 
propagation across the A VN, and in limiting the maximal number of beats conducted 
from atria to ventricles. 
The evidence that diet-induced HHcy in mice shortens the PR interval in the 
ECG and the AH interval in the intracardiac electrogram suggests accelerated conduction 
across the AVN78 • However, the mechanisms for increased AVN conduction were not 
elucidated in the study, and it remains to be determined whether A V nodal conduction 
changes are due to HHcy-induced GJC remodelling and/or overactivation of the NMDA-
R. Furthermore, an added level of complexity is presented by the potential effects of 
remodelling and cardiac NMDA-R activation on the slow and fast AVN pathways. To 
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explore these mechanisms a multidisciplinary approach that includes electrophysiological 
studies in combination with molecular techniques will be needed to understand the 
underlying changes in conduction properties of slow and fast pathways associated with 
HHcy. It remains to be determined whether the A VN pathways in HHcy will become 
slower due to fewer GlCs, lateralization of GlCs, and decreased Cx40 expression or 
whether they will have accelerated conduction due to increased GlC heterogeneity with 
greater ratios of Cx40 expression, and/or increased cardiac NMDA-R stimulation. 
Cardiac Electrophysiological Pacing and Recording 
The advent of clinical cardiac electrophysiology studies has provided a better 
understanding of A V junctional arrhythmias and the dual A V nodal pathway 
physiologl4 . In the last 8 years, techniques to record intracardiac electrical activity, as 
well as the ability to deliver impulses to the right atrium and ventricle of mice using 
programmed stimulation, have been developed54, 83, 85. To perform the 
electrophysiological studies, a 2Fr octopolar ring electrode catheter with 0.5mm electrode 
width and 0.5mm interelectrode distance is introduced into the right atrium and ventricle 
of the mouse via the right external jugular vein. Once the catheter tip is placed at the apex 
of the right ventricle, electrode pairs are selected to stimulate and record signals from the 
atria, A V node, and ventricles. Basic electrophysiologic variables are obtained using 
standard clinical electrophysiologic pacing protocols adjusted to the murine heart rate 
(-600 beats/min). Information gathered from these studies includes assessment of 
sinoatrial (SA)- and A V -nodal automaticity and conductivity as well as assessment of 
His-Purkinje system conductivity and refractoriness. It is also possible to study whether 
18 
mice have a propensity to develop atrial or ventricular tachyarrhythmias by using 
stimulation protocols that include up to three premature extra stimuli. 
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CHAPTER II 
HYPOTHESIS AND SPECIFIC AIMS 
Hypothesis 
Increased plasma homocysteine (Hcy) levels cause increased activation of cardiac 
NMDA receptors at the sinoatrial and atrioventricular nodes, increasing intracellular 
calcium and enhancing excitability of nodal cells, and thereby facilitating abnormalities 
in sinoatrial and atrioventricular conduction. This hypothesis was tested through three 
specific aims. 
Specific Aim 1 
To determine whether increased plasma Hcy, as observed in 
hyperhomocysteinemia (HHcy), affects cardiac conduction, surface electrocardiographic 
(ECG) data was obtained and programmed electrophysiological (EP) studies were 
performed in vivo to characterize conduction variables in wild-type C57BU6J mice and 
diet-induced hyperhomocysteinemic C57BU6J mice. Comparison of these data may 
illustrate any changes to cardiac conduction due to higher levels of plasma Hcy. 
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Specific Aim 2 
To investigate whether cardiac NMDA-R activation is involved in normal and/or 
pathologic cardiac conduction, pharmacological inhibitors of the NMDA receptor were 
utilized and ECG and EP variables at baseline were compared with those obtained 
following NMDA-R blockade. ECG and EP data were collected from wild-type 
C57BLl6J mice, diet-induced hyperhomocysteinemic C57BLl6J mice, and genetically-
induced hyperhomocysteinemic C57BLl6J mice. In a second set of experiments, HHcy 
was induced in wild-type C57BLl6J mice by intraperitoneal administration of Hcy 
solution in an acute infusion model. 
Specific Aim 3 
In order to compare expression levels of cardiac NMDA receptor in wild-type, 
diet- and genetically-induced hyperhomocysteinemic mice, immunoblotting was 
performed on hearts from animals from all three groups. Additionally, 
immunohistochemical identification of cardiac NMDA-R at the mouse atrioventricular 
node was undertaken. 
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Introduction 
CHAPTER III 
HYPERHOMOCYSTEINEMIA ALTERS SINOATRIAL 
AND ATRIOVENTRICULAR CONDUCTION 
Recently, remote telemetric ECG recordings from wild-type mice and mice with 
diet-induced hyperhomocysteinemia (HHcy) have been shown to display irregular 
cardiac rhythms74. In animals with diet-induced HHcy, long pauses in the ECG traces 
were recorded, indicating the presence of conduction abnormalities. HHcy is associated 
with hypertension, coronary artery disease, and cardiac interstitial fibrosis24. These risk 
factors induce structural and functional changes to the specialized conductive tissues as 
well as to the working myocardium, altering normal conduction. Conduction 
abnormalities increase the chance of creating substrate for the induction of ventricular 
tachycardia (VT) and possibly ventricular fibrillation (VFib). In the absence of 
intervention, VT degenerates into VFib and if not treated, ultimately sudden cardiac death 
ensues Several studies associate elevated Hcy with sudden cardiac death9, 14, 16. 
Additionally, several studies assert an association between HHcy and atrial 
fibrillation25, 28. Atrial fibrillation arises from extensive structural and electrical atrial 
remodelling. HHcy-induced MMP activation plays a role in the structural and electrical 
remodelling of the atria26, 27. Following orthotopic heart transplantation, HHcy is 
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associated with altered atrial electrical conduction manifesting as P wave dispersion28 . 
Hcy also modulates sodium and potassium currents in human atrial myocytes29, 30, 
highlighting another plausible mechanism by which elevated Hcy may initiate atrial 
arrh ythmias. 
My aim in this chapter was to investigate for the first time the 
electrophysiological characteristics of the cardiac conduction system in wild-type and 
hyperhomocysteinemic mice. The goal of these studies was to gain a better understanding 
of the effects of HHcy on sinoatrial and atrioventricular function. The hypothesis tested 
was that elevated plasma Hcy alters excitability of sinoatrial and atrioventricular nodal 
cells, resulting in abnormal nodal conduction. 
Methods 
Specific Aim 1 consisted of experiments performed on groups of 5 month old 
male C57BLl6J mice weighing 28-32g. In this set of studies, wild-type control mice (WT, 
total n= 17) and long-term diet-induced HHcy mice receiving 400 mg/L of homocystine, 
the dimerized form of Hcy, for a period of 12 weeks in their drinking water (DW, total 
n=16) were used to characterize electrocardiographic and electrophysiologic variables, 
including ventricular refractoriness and arrhythmia induction. 
Mice were housed 5 per cage and allowed ad libitum access to food and water in a 
facility with 12-hour light and dark cycles. All animals were housed and cared for in 
accordance with the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals (Department of Health and Human Services, Publication No. [NIH] 
86-23), the Association for the Assessment and Accreditation of Laboratory Animal 
23 
Care, and by the Institutional Animal Care and Use Committee of the University of 
Louisville. 
Electrocardiographic and EP Studies 
For each procedure, animals were anesthetized with 2,2,2-tribromoethanol (400 
mg/kg IP). Supplemental doses were administered as needed to maintain an adequate 
plane of anesthesia throughout the experiment. Anesthesia was monitored by checking 
the pedal reflex. Body temperature was maintained using a feedback system consisting of 
a rectal probe and a heating pad (Fine Science Tools, Foster City, CA). A lead II surface 
ECG was recorded during all procedures using subcutaneous needle electrodes, and RR, 
PR, QRS, and QT intervals were measured. Corrected QT (QTc) intervals were 
calculated using Bazett's formula86 . A right external jugular vein cannulation was 
performed to advance a 2-Fr octapolar catheter (CIBer mouse-EP; NuMED Inc., 
Hopkinton, NY) into the right atrium and ventricle. Intracardiac bipolar recordings were 
performed to verify catheter placement. Intracardiac electrogram recordings were 
obtained using a customized Biopac MP 150 recording/stimulation system controlled by 
Acknowledge software (Biopac Systems Inc., Goleta, CA). The catheter was manipulated 
to allow bipolar atrial stimulation, and recording of signals with clear visualization of the 
His bundle spike. The AH and HV intervals of intracardiac electro grams were measured. 
EP studies were performed using standard atrial and ventricular programmed stimulation 
protocols that were modified to accommodate mouse heart rates (~600 bpm). Mice were 
first paced from the right atrium and then paced from the right ventricle. Stimulation was 
performed using square waves with a pulse width of 2ms and with DC current set at twice 
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the diastolic threshold. The recording sampling rate of signals was 2kHz. EP variables 
measured included: sinus node recovery time (SNRT), corrected SNRT (CSNRT), 
Wenckebach periodicity (WP), 2: 1 AV block, AV nodal effective refractory period 
(A VNERP), right ventricular effective refractory period (RVERP) and arrhythmia 
induction using one and two premature ventricular stimuli. WP and 2: 1 A V block were 
assessed using programmed stimulation protocols in which basic cycle trains were 
reduced by 2.5ms decrements starting at an interval rate just below the intrinsic heart rate. 
The basic cycle length of trains in effective refractory period protocols was lOOms (S 1) 
and premature beats (S2) were serially reduced by 5ms decrements. 
Blood Analysis 
At the end of the EP studies, 300 to 500f..lL of blood were collected and 
centrifuged for 10 min at 10,000 rpm. The plasma was separated and frozen until 
analysis. Plasma Hcy was measured independently using a recombinant enzymatic 
cycling assay (Carolina Liquid Chemistries Corp., Winston-Salem, NC). The assay 
determines total plasma Hcy, which represents protein-bound Hcy plus free Hcy. Free 
Hcy encompasses the sulfhydryl form (HcyH), the dimerized form homocystine (Hcy-
Hcy), and Hcy-cysteine mixed disulfides. Values of plasma levels are reported as mean ± 
SEM. 
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Statistical Analysis 
Unpaired t-tests were performed to compare the means between groups for ECG 
and EP variables, as well as plasma Hcy values. Values are given as mean ± SEM for 
each group. A P value less than O.OS was considered significant. 
Results 
In the first experiment, we evaluated the effects of HHcy on surface ECG 
intervals, intracardiac electro grams , sinoatrial function, A V nodal conduction and 
ventricular conduction. Tables 1 and 2 summarize findings from this experiment. Surface 
ECG analysis revealed that the RR (l22.2±3.6 ms vs. 141.0±7.7 ms, P<O.OS), PR 
(46.6±2.0 ms vs. S3.8±2.6 ms, P<O.OS), and QT (S6.7±2.3 ms vs. 64.S±1.9 ms, P<O.OS) 
intervals were significantly shortened in mice with HHcy compared to controls (Table 1). 
The intracardiac HV interval was significantly shortened compared to controls (8.1±0.S 
ms vs. 1O.3±0.S ms, P<O.OI) while the AH interval was not significant (39.0±1.8 ms vs. 
44.0±2.3 ms, P=NS) in HHcy mice compared to controls (Table 1). Figure 1 shows 
representative surface and intracardiac electrograms obtained from WT and DW mice, and 
the shorter PR, and HV intervals observed in DW mice. Programmed atrial stimulation 
revealed that in HHcy there was a significant shortening of CSNRT (30.9±4.3 ms vs. 
Sl.2±3.0 ms, P<O.OO 1), WP (84.1±2.3 ms vs. 9S.9±2.S ms, P<O.O 1), 2: 1 A V block 
(73.8±1.8 ms vs. 81.2±2.4 ms, P<O.OS), AVNERP (SS.9±3.0 ms vs. 70.0±3.2 ms, 
P<O.OI), and RVERP (38.1±1.9 ms vs. S2.8±3.3 ms, P<O.Ol) as compared to controls 
(Table 2). Arrhythmia induction using one and two premature ventricular beats was 
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unsuccessful. Mean plasma levels of Hcy were 7.9±O.67 ,umollL in WT vs. 11.2±l.03 
,umollL in DW (P<O.05); the latter is considered to be mildly elevated. 
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Table 1. Comparison of Surface ECG and Intracardiac Electrograms. 
WT Control (n=17) DW(n=16) P 
RR interval (ms) 141.0±7.7 122.2±3.6 <0.05 
HR (bpm) 444.4±21.9 497.6±15.4 NS 
PR interval (ms) 53.8±2.6 46.6±2.0 <0.05 
QRS duration(ms) 18.4±0.4 17.4±0.7 NS 
QT interval (ms) 64.5±1.9 56.7±2.3 <0.05 
QTc interval (ms) 54.6±0.8 51.4±2.1 NS 
AH interval (ms) 44.0±2.3 39.0±1.8 NS 
HV interval (ms) 1O.3±0.5 8.1±0.5 <0.01 
His duration (ms) 3.3±0.1 3.3±0.1 NS 
WT, wild-type control; DW, mice receiving homocysteine (400mglL) in drinking water; 
HR, heart rate; NS, not significant. Values are mean ± SEM. 
28 
A. WT 
Lead II 
H 
Intracardiac 
HBE 
B. OW 
Lead II 
AH 
Intracardiac 
HBE 
H 
HV 
t--; 
HV 
Figure 1. Representative surface EeGs and intracardiac His bundle electrograms 
(HBE) from: A) a wild type control (WI) mouse, and B) a mouse receiving homocysteine 
(400mglL) in the drinking water for 12 weeks (DW). Notice shorter PR and HV intervals 
in mice receiving homocysteine compared to controls. 
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Table 2. Comparison of Atrial and Ventricular Programmed Stimulation Studies. 
CSNRT (ms) 
WP (ms) 
2: 1 A V Block (ms) 
AVNERP (ms) 
RVERP (ms) 
Arrhythmia induction % 
Atrial Stimulation 
WT Control (n=17) DW(n=16) 
51.2±3.0 30.9±4.3 
95.9±2.5 84.1±2.3 
81.2±2.4 73.8±1.8 
70.0±3.2 55.9±3.0 
Ventricular Stimulation 
WT Control (n=9) 
52.8±3.3 
o 
DW(n=8) 
38.1±1.9 
o 
P 
<0.001 
<0.01 
<0.05 
<0.01 
p 
<0.01 
WT, wild-type control; DW, mice receiving homocysteine (400mg/L) in drinking water; 
CSNRT, corrected sinus node recovery time; WP, Wenckebach periodicity; AVNERP, 
AV-nodal effective refractory period; RVERP, right ventricular effective refractory 
period. Arrhythmia induction was assessed using a train of 8 beats followed by two 
premature beats. Values are mean ± SEM. 
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Discussion 
The major finding of this study was that mild, diet-induced HHcy in mice 
shortens the PR and HV intervals, suggesting accelerated conduction across the A VN. 
These findings were supported by EP data demonstrating that CSNRT, WP, 2: 1 A V 
block, AVNERP, and RVERP were all significantly shorter in DW mice than in WT mice. 
These results indicate SA and A V nodal conduction abnormalities in mice with mild 
HHcy. There are several plausible mechanisms by which elevated Hcy may account for 
these changes. As discussed earlier, Hcy activates NMDA receptors, as well as modulates 
sodium and potassium channels. Activation of cardiac NMDA receptors, especially those 
at the SAN and AVN, allows more calcium influx, resulting in bathmotropic and 
dromotropic effects. High levels of Hcy increase sodium currents while inhibiting 
potassium currents in human atrial myocytes29, 30. Increased sodium currents enhance cell 
excitability, while inhibition of potassium currents prolongs action potential duration 
(APD). HHcy-induced modulation of cardiac sodium and potassium channels, as well as 
cardiac NMDA receptor activity, may produce the changes observed in this study. 
Additionally, HHcy induces oxidative stress by activating inducible nitric oxide 
synthase (iNOS) and NADPH oxidase7, 37, 38. As discussed previously, increased levels of 
myocardial iNOS are associated with arrhythmogenesis and SCD87 . HHcy increases 
mitochondrial oxidative stress of cardiomyocytes, increasing levels of reactive oxygen. 
species (ROS) which activate matrix metalloproteinases (MMPs) involved in 
extracellular matrix (ECM) remodelling8. Increased activation of MMPs is responsible 
for abnormal myocardial remodelling, which results in increased interstitial collagen 
associated with fibrosis 7. Homocysteine-activated MMP-mediated cardiac remodelling 
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likely alters the expression, distribution, and regulation of cardiac channels and receptors, 
ultimately modifying electrical continuity between cardiac cells. Cardiac remodelling in 
patients with heart failure57 , 58, 70, myocardial infarction6o-62 and likely, HHcy, is 
associated with various types of arrhythmias and conduction abnormalities. 
Impaired impulse conduction, as observed in this study, creates substrate for re-
entrant arrhythmias57 . These arrhythmias require 2 parallel conducting pathways 
connected proximally and distally by conducting tissue, thus forming a potential re-entry 
or circular electrical circuit. For re-entry to occur 3 prerequisites need to be present: 1) 
one of the 2 pathways conducts more slowly, 2) the faster conducting pathway has a 
substantially longer refractory period, and, 3) an appropriately timed premature impulse 
is needed to initiate a continuous circular propagation of the impulse. Anatomically in the 
mouse and most mammals, the AVN is not a discrete entity, and the modern view 
describes it as a dual atrioventricular transmission system wherein diffuse fibers arising 
in the right atrium coalesce into two pathways which approach the central, compact body 
of the A VN 79, 80. The anterior pathway, which runs along the Tendon of Todaro, has been 
determined to be the fast (or normal) pathway with a longer refractory period. The 
posterior pathway, running along the tricuspid annulus, comprises the slow pathway with 
a shorter refractory period. The existence of dual pathways with differing conduction 
velocities has been hypothesized to be the substrate for A V nodal re-entrant 
supraventricular arrhythmias 79, 81 
The mechanisms for accelerated nodal conduction were not elucidated in the 
study, and it remains to be determined whether SA and A V nodal conduction changes are 
due to HHcy-induced modulation of ion channel activity and/or MMP-induced cardiac 
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remodelling. To explore these mechanisms a multidisciplinary approach that includes 
electrophysiological studies in combination with molecular techniques will be needed to 
understand the underlying changes in conduction properties associated with HHcy. 
Conclusions 
The results of this study show acceleration of SA nodal and A V nodal conduction 
in HHcy. These findings suggest that acceleration of conduction has the potential to 
create substrate that ultimately may lead to arrhythmogenesis. 
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CHAPTER IV 
HYPERHOMOCYSTEINEMIA-INDUCED CONDUCTION ABNORMALITIES ARE 
ASSOCIATED WITH CARDIAC NMDA RECEPTOR 
Introduction 
The NMDA receptor has been extensively studied in the CNS - its role in 
excitatory neurotransmission, synaptic plasticity, and memory formation has been well 
documented. It is known that homocysteine can activate the NMDA-R in the brain I. 
Extraneuronal expression of NMDA receptors has been established in the heart, lungs, 
kidneys, gastrointestinal tract, ovaries, and testes2. In the heart, the receptor has been 
identified in cardiomyocytes of the working myocardium, as well as in the specialized 
d ·· fhh 5634 h ·f· h .. I con uctIve tIssues 0 t e eart" , owever Its unctIOn at t ese SItes IS poor y 
understood. 
Recent studies characterizing the decrease in cardiomyocyte contractility that is 
observed in HHcy implicate a role for cardiac NMDA receptors. Use of MK-801, a 
specific non-competitive NMDA-R antagonist, attenuates the contractile dysfunction 
observed in HHcy88. Further studies using cardiomyocyte-specific deletion of NMDA-Rs 
in the murine heart also show improvements in contractile function of isolated 
cardiomyocytes89. Additionally, in remote telemetric ECG studies in 
hyperhomocysteinemic mice treated with MK -801, significant prolongation of RR, PR, 
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QRS, QT, and QTc is observed74 . Animals treated with Hcy alone or MK-801 alone have 
prolonged QT/QTc intervals over control animals, and animals treated with both Hcy and 
MK-80ltogether have even longer QT/QTc intervals. This may implicate homocysteine 
as well as the NMDA-R in the etiology of long QT syndrome. Taken together, it can be 
suggested that Hcy is acting on cardiac NMDA-Rs to effect the changes observed in 
HHcy. 
My aim in this chapter was to investigate whether activation of cardiac NMDA 
receptors by Hcy underlies changes in conduction observed in diet-induced HHcy. I 
tested the hypothesis that elevated levels of Hcy increase activation of cardiac NMDA-Rs 
at the SA and A V nodes, altering sinoatrial and atrioventricular impulse conduction. The 
approach was to delineate a role for cardiac NMDA-Rs by comparing ECG and EP 
variables before and after NMDA-R blockade. A specific blocker (MK-801) and a non-
specific blocker (MgS04) were selected to test the hypothesis, but ultimately Mg2+ 
blockade proved to have fewer confounding effects and was used in the study. 
Materials and Methods 
Study Design 
Specific Aim 2 consisted of two sets of experiments performed on male 
C57BLl6J mice weighing 28-32g. In the first set of experiments, the feasibility of using 
an acute intraperitoneal infusion model of HHcy with specific NMDA-R blockade using 
MK-801 was explored. Hcy and MK-801 dose response studies were performed in wild-
type C57BLl6J following baseline measurements of ECG and/or EP variables as 
described previously. ECG and EP variables were measured at 30-minute intervals for up 
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to 60 minutes. Minimal doses of Hcy eliciting conduction abnormalities and minimal 
doses of MK-801 which did not affect conduction were sought in these experiments. 
Once the minimal doses were established three experimental groups were studied: Hcy 
only group, MK-801 only group, and Hcy and MK-801 group where MK-801 was 
administered 30 minutes after Hcy administration. Blood was collected at the end of each 
experiment for plasma analysis as described previously. 
In the second set of experiments, a long-term HHcy mouse model with non-
specific NMDA-R blockade using MgS04 was utilized. Mg2+ is an endogenous blocker 
of the NMDA-R, a fact which gives rise to the receptor's voltage-dependence. In a pilot 
study, it was determined that a dose of 20mg/kg of MgS04 was ideal as it did not appear 
to have a confounding effect on mouse ECG variables. These experiments were 
performed on 20 week-old male C57BLl6J and heterozygous cystathionine ~-synthase 
knockout mice (C57BLl6J_CBStml-Unc The Jackson Laboratory, Bar Harbor, ME) mice 
weighing 28-32g. A paired-design study was performed on the following groups: wild-
type controls (WT, n=8), diet-induced HHcy receiving 400 mg/L of homocystine in the 
drinking water for 12 weeks (DW, n=8), and C57BLl6J_CBStml-Unc mice (CBS+1-, n=7) 
were subjected to a baseline EP study followed by a repeat EP study 30 minutes after 
intraperitoneal (IP) administration of MgS04 (20mg/kg) in phosphate buffer saline 
(PBS). 
Mice were housed 5 per cage and allowed ad libitum access to food and water in a 
facility with 12-hour light and dark cycles. All animals were housed and cared for in 
accordance with the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals (Department of Health and Human Services, NIH Publication No. 
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86-23), the Association for the Assessment and Accreditation of Laboratory Animal 
Care, and by the Institutional Animal Care and Use Committee of the University of 
Louisville. 
Electrocardiographic and EP Studies 
For each procedure, animals were anesthetized with 2,2,2-tribromoethanol (400 
mg/kg IP). Supplemental doses were administered as needed to maintain adequate 
anesthesia throughout the experiment. Anesthesia was monitored by checking the pedal 
reflex. Body temperature was maintained using a feedback system consisting of a rectal 
probe and a heating pad (Fine Science Tools, Foster City, CA). A lead II surface ECG 
was recorded during all procedures using subcutaneous needle electrodes, and RR, PR, 
QRS, and QT intervals were measured. Corrected QT (QTc) intervals were calculated 
using Bazett's formula86• A right external jugular vein cannulation was performed to 
advance a 2-Fr octapolar catheter (CIDer mouse-EP; NuMED Inc., Hopkinton, NY) into 
the right atrium and ventricle. Intracardiac bipolar recordings were performed to verify 
catheter placement. Intracardiac electrogram recordings were obtained using a 
customized Biopac MP 150 recording/stimulation system running Acknowledge software 
(Biopac Systems Inc., Goleta, CA). The catheter was manipulated to allow bipolar atrial 
stimulation, and clear visualization of His bundle spike. The AH and HV intervals of 
intracardiac electro grams were measured. EP studies were performed using standard 
programmed stimulation protocols that were modified to accommodate mouse heart rates 
(-600 bpm). The heart was paced from the right atrium. Stimulation was performed using 
square waves with a pulse width of 2ms and with DC current set at twice the diastolic 
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threshold. The recording sampling rate of signals was 2kHz. EP variables measured 
include: sinus node recovery time (SNRT), corrected SNRT (CSNRT), Wenckebach 
periodicity (WP), 2: 1 A V block, A V nodal effective refractory period (A VNERP), and 
arrhythmia induction using one and two premature ventricular stimuli. WP and 2: 1 A V 
block were assessed using programmed stimulation protocols in which basic cycle trains 
were reduced by 2.5ms decrements. The basic cycle lengths of trains in A VNERP 
protocols in mice receiving Mg2+ were 100, 110, and 120ms, and were performed when 
heart rates allowed it. A VNERPs from the baseline and repeat EP studies were compared 
at the equivalent S 1 cycle length. Premature beats (S2) in all studies were reduced by 5ms 
decrements. 
Blood Analysis 
At the end of the EP studies, 300 to 500~L of blood were collected and 
centrifuged for 10 min at 10,000 rpm. The plasma was separated and frozen until 
analysis. Plasma Mg2+ levels were measured using a clinical chemistry Beckman-Coulter 
DxC 800 instrument (Beckman-Coulter, Brea, CA). It should be pointed out that total 
Mg2+ levels (free + bound Mg2+) were measured in the present study, however, free Mg2+ 
constitutes the active form. Values of plasma levels are reported as mean ± SEM. Hcy 
was measured independently using a recombinant enzymatic cycling assay (Carolina 
Liquid Chemistries Corp., Winston-Salem, NC). The assay determines total plasma Hcy, 
which represents protein-bound Hcy plus free Hcy. Free Hcy encompasses the sulfhydryl 
form (HcyH), the dimerized form homocystine (Hcy-Hcy), and Hcy-cysteine mixed 
disulfides. Values of plasma levels are reported as mean ± SEM. 
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Statistical Analysis 
Single-factor ANOV A and unpaired t-tests were performed to compare the means 
between groups for ECG and EP variables, as well as plasma Hcy and Mg2+ values. 
Paired t-tests were performed to compare means within a group before and after Mg2+ 
administration. Values are given as mean ± SEM for each group. A P value less than 0.05 
was considered significant. 
Results 
In the first set of experiments to determine minimal doses of Hcy eliciting 
conduction changes, acute intraperitoneal infusion of very high doses consisting of 100 
and 200 mg/kg did not elicit any significant changes in PR interval, WP, 2: 1 AV block, 
and AVNERP at 30 and 60 minutes. These findings are illustrated in Figures 2 and 3. 
Conversely, in experiments using the NMDA-R blocker MK-801, extremely pronounced 
changes in the PR interval, WP, 2: 1 AV block, and A VNERP were observed following 
administration of blocker at very low doses (0.05, 0.16, or 0.25 mg/kg). These changes 
are illustrated in Figures 4 and 5. 
39 
PR Interval 
60 
50 
40 
• Baseline 
III 
E 30 . 30mins 
20 . 60mins 
10 
0 
100mg/kg Hey 200mg/kg Hey 
Wenckebach Periodicity 
100 
80 
III 60 • Baseline 
E . 30mins 
40 . 60mins 
20 
o 
100mg/kg Hey 200mg/kg Hey 
Figure 2. PR interval (top panel) and Wenckebach periodicity (bottom panel) in 
wild-type C57BL6 mice at 30 and 60 minutes following acute intraperitoneal 
administration of 100 or 200 mg/kg homocysteine 
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Figure 3. 2: 1 A V block (top panel) and A V nodal effective refractory period 
(A VNERP, bottom panel) in wild-type C57BL6 mice at 30 and 60 minutes following 
acute intraperitoneal administration of 100 or 200 mg/kg homocysteine 
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Figure 4. PR interval (top panel) and Wenckebach periodicity (bottom panel) in 
wild-type C57BL6 mice 30 minutes following acute intraperitoneal administration of 
0.05, 0.16, or 0.25 mg/kg MK801 , a non-competiti ve NMDA receptor antagonist. 
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Figure 5. 2: 1 A V block (top panel) and A V nodal effective refractory period 
(A VNERP, bottom panel) in wild-type C57BL6 mice 30 minutes following acute 
intraperitoneal administration of 0.05 , 0.16, or 0.25 mg/kg MK801 , a non-competitive 
NMDA receptor antagonist. 
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In the second set of experiments, surface ECG and intracardiac electrogram 
changes before and after intraperitoneal administration of MgS04 (20mg/kg) in WT, DW 
and CBS+1- groups are shown in Figures 6-8. Administration of Mg2+ increased duration 
of RR, PR, QRS and QTc intervals, as well as AH and HV intervals in DW, but had little 
to no effect on CBS+1- and WT controls. Figure 9 shows EP variables before and after 
intraperitoneal Mg2+ in all three groups. Mg2+ administration had no effect on WT 
animals, but had a marked effect on both the DW and CBS+1- animals. WP, 2: 1 A V block, 
and A VNERP were all significantly prolonged following administration of MgS04 in 
DWand CBS+1- animals, and CSNRT was significantly prolonged in DW mice. 
There was no significant difference between Mg2+ plasma levels in all groups 
from blood samples collected at the end of EP studies. Normal Mg2+ plasma levels in 
wild-type animals before receiving intraperitoneal Mg2+ were 1.50±O.20mmollL. In 
animals receiving intraperitoneal Mg2+ the levels were 1.65±O.24mmollL in WT, 
1.71±O.22mmollL in DW, and 1.40±O.17mmollL in CBS+1-. There were significant 
differences in plasma Hcy levels between WT mice (8.43±2.75IlmollL), DW mice 
(11.16±2.91IlmollL, P<O.02 compared to WT) and CBS+1- mice (13.04±4.49IlmollL, 
P<O.02 compared to WT). There was no difference in Hcy levels between DW and CBS+1-
mIce. 
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Figure 6. A. Surface ECG variables in wild-type (WI) animals at baseline (Pre-Mg2+) 
and following MgS04 administration (Post-Mg2+). B. Intracardiac ECG variables in WT 
animals at baseline (Pre-Mg2+) and following MgS04 administration (Post-Mg2+). AH= 
Intracardiac interval measuring time between atrial depolarization and depolarization of 
the His bundle. HV= Intracardiac interval measuring infra-Hisian conduction. 
45 
A. 
160 
140 
DW 
120 
'iii 100 
E - 80 • Pre-Mg2+ Qj 
E 
• Post-Mg2+ j:: 60 
40 
20 
0 
RR PR QRS QT 
B. 
60 
50 DW 
_40 
III 
E 
-; 30 • Pre-Mg2+ 
E • Post-Mg2+ j:: 
20 
10 
0 
AH HV 
Figure 7. A. Surface ECG variables in diet-induced hyperhomocysteinemia (DW) 
animals at baseline (Pre-Mg2+) and following MgS04 administration (Post-Mg2+). B. 
Intracardiac ECG variables in DW animals at baseline (Pre-Mg2+) and following MgS04 
administration (Post-Mg2+) . AH= Intracardiac interval measuring time between atrial 
depolarization and depolarization of the His bundle. HV= Intracardiac interval measuring 
infra-Hisian conduction. 
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Figure 8. A. Surface ECG variables in genetically-induced hyperhomocysteinemia 
(CBS+1-) animals at baseline (Pre-Mg2+) and after 30 minutes following MgS04 
administration (Post-Mg2+). B. Intracardiac ECG variables in CBS+1- animals at baseline 
(Pre-Mg2+) and after 30 minutes following MgS04 administration (Post-Mg2+). AH= 
Intracardiac interval measuring time between atrial depolarization and depolarization of 
the His bundle. HV= Intracardiac interval measuring infra-Hisian conduction. 
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Figure 9. EP variables in wild-type (W7),diet-induced HHcy (DW), and genetically-
induced HHcy (CBS+1-) animals at baseline (Pre-Mg2+) and following MgS04 
administration (Post -Mg2+) 
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Discussion 
The major finding of this study was that administration of the non-specific, 
endogenous NMDA-R antagonist MgS04 prolonged AV nodal conduction in both diet-
induced and genetically-induced HHcy, but not in wild-type animals. Additionally, an 
attempt to establish an acute model of HHcy via intraperitoneal infusion of Hcy was not 
successful in replicating results obtained from using chronic models of HHcy (such as 
dietary intake of Hcy for 12 weeks, or by genetic CBS knockout). No changes in ECG or 
EP variables were observed following intraperitoneal administration of high levels of 
Hcy, even after 120 minutes post-administration. These findings suggest that acute 
infusion of Hcy does not elicit the effects observed in our long-term models of chronic 
HHcy. Indeed, a recent report demonstrates that Hcy accumulation in tissues does not 
necessarily reflect plasma levels, and therefore tissue levels must be considered when 
anal yzing the effects of plasma Hcy on target organs 12. 
To delineate a role for cardiac NMDA-Rs in HHcy-induced conduction 
abnormalities, MK-801, a specific and noncompetitive NMDA-R antagonist, was 
utilized. MK-801 produces sustained elevations in mean arterial pressure and heart rate 
when administered systemically at therapeutic doses9o. Pilot studies were undertaken to 
determine a low dose of MK-801 which would not alter ECG and EP variables too 
drastically; however, at doses considerably lower than published therapeutic or 
experimental doses, the heart rate slowed considerably, suggesting that the blocker was 
inducing central effects. The use of alternative specific NMDA-R blockers (like 2-amino-
5-phosphonovaleric acid and memantine) was avoided because they would induce similar 
effects as MK-801, affecting cardiovascular reflexes and neural tone90-92, which would 
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confound results from EP studies. 
The evidence presented regarding the role of the NMDA-R in shortening A V 
conduction time is based on the effects of Mg2+, a known NMDA-R modulator. 
Electrophysiological effects of Mg2+ have been known clinically for over 70 years. Mg2+ 
has been used in the management of patients with torsades de pointes, atrial flutter, 
paroxysmal A V re-entrant supraventricular tachycardia and Wolff-Parkins on-White 
(WPW) syndrome93• 94. In the present study, low-dose Mg2+ blockade was selected based 
on results from pilot studies. In these studies, the lowest Mg2+ dose (90mg/kg) reported to 
block central NMDA-Rs in rodents95 produced severe bradycardia in the C57BLl6J mice 
used in the present study; thus, the Mg2+ dose was further lowered to 20mg/kg, to the 
point where no discernible effects on heart rate or blood pressure were observed. Mg2+ 
blood levels at the end of the second EP study were in the normal range indicating that 
peak levels following IP administration were not excessively high. In the present study, 
this dose had no effect on ECG and EP variables in WT mice. Pilot studies determined 
that plasma Mg2+ levels peaked between 40 and 50 minutes following IP administration. 
EP studies were started 30 minutes post-administration to coincide with peak Mg2+ blood 
levels. Elevation of extracellular Mg2+ interferes with the release of the Mg2+ channel 
block present in NMDA receptors, and thus reduces inward Ca2+ flow via this channe195 . 
In most human studies, Mg2+ administration increases cardiac conduction time to some 
degree; however, there is disagreement as to which conduction variables are affected. 
Rassmussen et al. and DiCarlo et al. demonstrate that Mg2+ treatment prolongs PR 
interval, QRS duration, A V nodal (AH) conduction time and A V nodal functional 
refractory period, but has no effect on sinus node function96• 97. Alternatively, Kulick et 
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al. demonstrate that Mg2+ administration prolongs PR interval, AH interval, and A V 
nodal effective refractory period but has no significant effect on QRS duration, QT 
interval, HV interval, WP, and AVNERp98. Differences reported in these studies can be 
attributed to the lower plasma Mg2+ levels achieved by Kulick's group. Indeed, in canine 
studies, low-dose Mg2+ administration elicited few conduction changes, but as dosing and 
levels of serum Mg2+ increase (up to 6.5±2.1 mmollL), a progressive prolongation in AH 
interval, HV interval, QRS duration, WP, AVNERP and RR cycle length is observed, 
while arterial blood pressure falls99. Thus, low-dose administration of Mg2+ appears to 
have little effect on cardiac conduction and EP variables. The Mg2+ dose used in the 
present study appears to unmask Hcy-induced effects via cardiac NMDA-Rs because 
changes in conduction were only observed in mice with HHcy but not in WT mice 
receiving the same therapy. 
The findings from the present study provide modest support to the hypothesis that 
increased levels of Hcy overstimulate cardiac NMDA-Rs, causing an increase in 
intracellular calcium [Ca2+]j during depolarization, leading to increased nodal cell 
excitation and A V nodal conduction. This hypothesis was based on literature indicating 
that activation of NMDA-Rs by excitatory amino acids increases intracellular calcium 
[Ca2+]j, which in some cases leads to Ca2+ overload6, 100, 101. Hcy increases NMDA-R 
activity by interacting with both glycine and glutamate binding sites, and the activation is 
enhanced when glycine levels are above normal I. Hcy-induced NMDA-R activation 
increases cell excitability in various cell types3, 4,88,89,102,103, and the results from the 
present study suggest that cardiac NMDA-Rs behave similarly, particularly those 
expressed in A V nodal cells. HHcy is known to increase [Ca2+]j in various cells 
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expressing NMDA-Rs, including neural cells l , 103, smooth muscle cells\o2, endothelial 
cells3,4, and cardiomyocytes88, 89. Although the NMDA-R is expressed in cells of the A V 
node, bundle of His and Purkinje fiber system, this receptor's role in normal or 
pathologic cardiac conduction is largely unknown. Future studies using cardiac 
conduction system-restricted NMDA-R knockout mice will be necessary to elucidate 
more specifically the mechanisms by which HHcy alters atrioventricular conduction. 
Conclusions 
The mechanisms associated with conduction changes observed in mild HHcy 
appear to involve stimulation of cardiac NMDA-Rs by Hcy. Blockade of NMDA-R with 
low-dose Mg2+ prolonged conduction time in animals with HHcy but had no effect on 
normal controls. The results of this study provide evidence that atrioventricular 
conduction abnormalities associated with HHcy may involve increased stimulation of A V 
nodal cardiac NMDA-Rs, which may provide substrate for arrhythmogenesis. 
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CHAPTER V 
CARDIAC NMDA RECEPTOR EXPRESSION IN MILD HYPERHOMOCYSTEINEMIA 
Introduction 
Modulation of NMDA receptors in different tissues is associated with various 
pathologic conditions including HHcy. Ethanol is a potent, selective inhibitor of NMDA-
R function, and chronic ethanol consumption causes an adaptive upregulation of central 
NMDA R RNA .. 11 . . 104 105 In .. - m transcnptIOn as we as protem expreSSIOn ' . gentamlcm-
induced nephrotoxicity, both mRNA and protein levels of the obligatory NRI subunit of 
kidney NMDA-R are increased in renal proximal tubules, and treatment with the NMDA-
R antagonist MK-801 ameliorates tubular injury l06. Several lines of evidence demonstrate 
modulation of NMDA-R expression in HHcy. Elevated homocysteine upregulates 
expression ofNMDA receptor NRI subunit mRNA and protein in rat aortic endothelial 
cells3 and rat aortic smooth muscle cells4. In uni-nephrectomized rats fed a folate-free 
diet for 6 weeks to induce HHcy, glomerular NRI and NR2C subunits are upregulated, an 
effect that is attenuated by MK-801 107 . Chronic HHcy also enhances long-term 
potentiation (LTP) in rat hippocampus, suggesting an upregulation of NMDA-R 
expression 108. In the brain, LTP underlies the processes of learning and memory 
formation, and is mediated by NMDA-R activity. 
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In this chapter, I examined whether the electrophysiological changes observed in 
mild HHcy are in part explained by differences in cardiac NMDA-R expression. My aim 
was to investigate cardiac NMDA-R expression levels by Western blot analysis of total 
NMDA receptor NRI subunit expression in whole heart, as well as to characterize NRI 
expression at the murine A V node by immunohistochemical analysis. I hypothesized that 
NMDA-R expression levels in the heart, and in particular at the A V node, differ based on 
duration of exposure to elevated Hcy. To test this hypothesis, levels of cardiac NMDA-R 
expression were quantified, and NRI subunit expression at the AV node was 
characterized. 
Methods 
Study Design 
Specific Aim 3 consisted of two sets of experiments performed on male 
C57BU6J mice weighing 28-32g. In the first set of experiments, total cardiac 
expression of NR 1 was studied in three experimental groups of animals: wild~type control 
(WT, n=3), diet-induced HHcy receiving 400 mg/L of homocystine in the drinking water 
for 12 weeks (DW, n=3), and heterozygous CBS knockouts (CBS+1-, n=3). In the second 
set of experiments, wild-type (WT, n=4) C57BU6J mice were utilized for 
immunohistochemical identification of NMDA receptor NRI subunit at the murine AV 
node. 
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Western Blotting 
Hearts from WT, DW, and CBS+1- mice were harvested at the end of the 
experiment and frozen in liquid nitrogen. Cardiac tissue homogenates were prepared from 
whole hearts using protein extraction buffer (RIPA buffer, Sigma Aldrich, St. Louis, 
MO). The extracted protein was collected by centrifugation at 1500 g for 10 minutes. The 
supernatant was collected and centrifuged again until the aqueous portion was clear. 
Protein content was estimated using a BCA protein assay kit (Thermo Scientific, 
Rockford, IL). Equal amounts of protein were separated by SDS-PAGE on 12% Tris-
glycine gels (Bio-Rad), transferred onto PVDF membrane overnight, and probed with a 
polyclonal anti-NRI antibody (Abc am Inc., Cambridge, MA) conjugated with 
horseradish peroxidase (HRP). Enhanced chemiluminescence reagents were applied and 
band intensity was recorded and analyzed with a Kodak image analyzer (Perkin-Elmer, 
Waltham, MA) 
Immunohistochemistry 
Hearts from WT mice were harvested and fixed by coronary perfusion with 8% 
paraformaldehyde. The free wall of the right ventricle was removed, as was most of the 
right atrium, in order to gain access to the A V junction. Tissue samples were stored in 
8% paraformaldehyde until they were embedded in paraffin (a suture was tied to the apex 
of the heart for orientation), and sectioned transversely beginning at a level just superior 
of the tricuspid valve. HRP-conjugated polyclonal anti-NRI antibody (Abcam Inc., 
Cambridge, MA) was used to probe for NMDA-R expression. Diaminobenzidine (DAB) 
was used as a chromogen. 
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Statistics 
Single-factor ANOV A and unpaired t-tests were performed to test for significance 
between groups. Values are given as mean ± SEM for each group. A P value less than 
0.05 was considered significant. 
Results 
To characterize and compare cardiac NMDA-R expression in hearts from the 
three experimental groups, Western blotting for NMDA receptor NRI subunit in whole 
heart was performed. Western blotting analysis showed a significant decrease of NR 1 
expression in CBS+1- hearts compared to WThearts (P<0.05) and DWhearts (P<0.05). 
Figure 10 shows the densitometric means from the three groups. 
In order to identify NMDA-R NR 1 subunit expression at the murine A V node, 
immunohistochemical analysis of dissected A V junction tissue was undertaken. Figures 
11-12 show representative images of sections of A V tissue stained with hematoxylin and 
eosin, and probed for NRI expression. Positive immunoreactivity for NRI is indicated by 
brown punctate staining as well as diffuse brown staining of tissue. These results were 
difficult to interpret since the A V node is not a discrete structure that is easily identified 
due to the small size of mouse heart. 
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Figu re 10. Relative abundance of NR I subunit of NMDA receptor in wild-type (WT, 
n=3), genetically- induced hyperhomocysteinemic (CBS+1-, n=3), and diet-induced 
hyperhomocysteinemic (DW, n=3) mouse hearts. NR I expression in CBS+1- is 
significantly decreased compared to WT as well as DW. 
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Figure 11. Tissue at the murine atrioventricular junction stained with hematoxylin and 
eosin and probed with anti-NRI polyclonal antibody conjugated with horseradish 
peroxidase. Diarninobenzidine was used as a chromogen. 20X magnification shown. 
Positive immunoreactivity for NRI is indicated by brown punctate staining as well as 
diffuse brown staining of cardiomyocytes (arrows). 
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Figure 12. Tissue at the murine atrioventricular junction stained with hematoxylin and 
eosin and probed with anti-NRI polyclonal antibody conjugated with horseradish 
peroxidase. Diaminobenzidine was used as a chromogen. 40X magnification shown. 
Positive immunoreactivity for NRI is indicated by brown punctate staining (arrows) . 
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Discussion 
The major finding from this study was that in life-long, genetically-induced 
HHcy, the cardiac NMDA-R appears to be down-regulated compared to WT animals as 
well as animals with diet-induced HHcy. The difference in NMDA-R NR1 subunit 
expression between the CBS+1- and DW groups may be associated with the duration of 
exposure to elevated Hcy, life-long versus 12 weeks respectively. The results suggest that 
life-long HHcy in CBS+1- mice induces a down-regulation of cardiac NMDA-R 
expression. Interestingly, plasma Hcy levels were similar in CBS+1- and DW groups; 
however down-regulation of cardiac NMDA-R NR1 subunit expression was only 
observed in CBS+1-. Moreover, NR1 expression was significantly higher in DW compared 
to CBS+1-. In the literature, conflicting evidence exists regarding the effect of increased 
agonism of NMDA-R in different cells/tissues on receptor expression. A rapid down-
regulation (within 3 hours) ofNMDA-R NR1 subunit occurs when cerebellar granule 
cells are treated with NMDA, the most potent agonist of the receptor lO9 . Other studies 
demonstrate upregulation of NR 1 in HHcy. In cultured rat aortic endothelial cells, 
simulating moderate levels of HHcy (50!lM of Hcy) causes increasing NR1 subunit 
expression that peaks at 6 hours3. In rat vascular smooth muscle cells, moderate levels of 
HHcy produce an increase in expression of NR1 which peaks at 12 hours post-treatment4• 
In vivo studies using uni-nephrectomized rats fed a folate-free diet for 6 weeks to induce 
mild HHcy demonstrate upregulated glomerular NR 1 expression 107. Based on these 
studies, the expectation was that an upregulation of cardiac NMDA-R would occur in 
CBS+1- and DW animals. However, a down-regulation was observed in CBS+1- animals 
compared to WT, and no change was observed in DW animals compared to WT animals. 
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A plausible explanation for the findings in CBS+1- mice is that in life-long HHcy, a 
compensatory down-regulation of NMDA-R expression in the heart may occur during 
early embryonic development, and expression remains down-regulated throughout 
adulthood. An explanation as to why DWanimals did not demonstrate upregulation of 
NRI may be related to the lower plasma levels of Hcy achieved in DW mice (11.36±1.03 
!AM) compared to those reached (16!AM) in uni-nephrectomized rats fed a folate-free diet, 
which did exhibit upregulation of glomerular NRI expression. Thus it appears that 
receptor agonism can induce both upregulation and/or down-regulation of NMDA-R 
expression in different tissues, and is dependent on the agonist used as well as the 
duration of exposure to the agonist. Elevated Hcy primarily upregulates short-term 
receptor expression, but modulation may be dependent on plasma Hcy levels. 
Furthermore, modulation of receptor expression may be dependent on tissue type; in the 
present study, expression of NMDA-R in heart may exhibit decreased propensity towards 
upregulation as compared to the kidney, as observed in animals fed a folate-free diet for 6 
weeks 107. 
NRI expression in the cardiac conduction system has been successfully 
characterized in larger mammals, such as rat, primate, and human. The larger size of the 
hearts in these animals precludes the difficulties associated with micro-dissection of a 
very small region of tissue. Prior immunohistochemical characterization of NR 1 
expression at the murine A V node had not been accomplished, possibly due to the small 
size of the mouse heart and the technical challenges inherent in micro-dissection of 
murine A V nodal tissue. Notwithstanding this challenge, to this author's knowledge this 
is the first attempt to identify NMDA-R expression at the A V junction in mouse heart. 
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Conclusions 
Expression levels of cardiac NMDA-R were significantly decreased in 
genetically-induced HHcy, compared to diet-induced HHcy and controls. It appears that 
the electrophysiological changes observed in animals with HHcy are not due to receptor 
modulation, since the electrophysiologically-similar CBS+1- and DW animals exhibited 
significantly dissimilar cardiac NMDA-R expression levels. 
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CHAPTER VI 
SUMMARY AND FUTURE DIRECTIONS 
Hyperhomocysteinemia (HHcy) is a risk factor for cardiac arrhythmogenesis. 
Increased plasma homocysteine (Hcy) accelerates sinoatrial and atrioventricular 
conduction, as measured by electrophysiological studies. These findings suggest that 
acceleration of conduction has the potential to create substrate which ultimately may lead 
to arrhythmogenesis. 
The mechanisms associated with conduction changes observed in mild HHcy 
appear to involve stimulation of cardiac N-methyl-D-aspartate receptors (NMDA-Rs) by 
Hcy. Blockade of NMDA-R with low-dose Mg2+ prolonged conduction time in animals 
with HHcy but had no effect on normal controls. Sinoatrial and atrioventricular 
conduction abnormalities associated with HHcy may involve increased stimulation of 
nodal cardiac NMDA-Rs, which may provide substrate for arrhythmogenesis. 
Expression levels of cardiac NMDA-R were significantly decreased in 
genetically-induced HHcy, compared to diet-induced HHcy and controls. It appears that 
the electrophysiological changes observed in animals with HHcy are not due to receptor 
modulation, since the electrophysiologically-similar CBS+1- and DW animals exhibited 
significantly dissimilar cardiac NMDA-R expression levels. 
63 
Future investigation is necessary to unequivocally determine the role of cardiac NMDA-
R in Hcy-induced arrhythmias. Conditional knock-out technology, wherein genetic 
deletion of the protein of interest can be limited to one organ or one tissue, may be used 
to further delineate the role of cardiac NMDA-R in normal or pathological cardiac 
conduction. Additionally, it is necessary to investigate all known pathways in which Hcy 
exerts an influence. It may be through a direct interaction with a receptor like the cardiac 
NMDA-R, or through indirect means involving activation of MMPs and subsequent 
cardiac remodelling, that Hcy is able to evoke conduction abnormalities which underlie 
arrh ythmogenesis. 
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